A wearable electrocardiogram (ECG) device is to be distributed more widely after the company that developed it, Cardiac Insight, raised $4.5man additional $4.5m in funding. Patients displaying “transient symptoms” of heart conditions wear the Cardeo Solo monitoring device for a week, collecting data that doctors can use to instantly diagnosis cardiac anomalies if they exist. Cardiac Insight, which spun out of the University of Washington in 2008, also raised an additional $4.5m in April, the same month the Cardeo Solo received FDA approval. Pricing is yet to be announced for the small, disposable device, currently being sold to hospitals and cardiologists.
A wearable electrocardiogram (ECG) device is to be distributed more widely after the company that developed it, Cardiac Insight, raised an additional $4.5m in funding. Patients displaying “transient symptoms” of heart conditions wear the Cardeo Solo monitoring device for a week, collecting data that doctors can use to instantly diagnosis cardiac anomalies if they exist. Cardiac Insight, which spun out of the University of Washington in 2008, also raised $4.5m in April, the same month the Cardeo Solo received FDA approval. Pricing is yet to be announced for the small, disposable device, currently being sold to hospitals and cardiologists.